ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. **NAME OF THE MEDICINAL PRODUCT**

Deltyba 50 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each film-coated tablet contains 50 mg delamanid.

**Excipient with known effect**

Each film-coated tablet contains 100 mg lactose (as monohydrate).

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Film-coated tablet (tablet)

Round, yellow, film-coated tablet, 11.7 mm in diameter, debossed with ‘DLM’ and ‘50’ on one side.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4.2, 4.4 and 5.1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 **Posology and method of administration**

Treatment with delamanid should be initiated and monitored by a physician experienced in the management of multidrug-resistant *Mycobacterium tuberculosis*.

Delamanid must always be administered as part of an appropriate combination regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) (see sections 4.4 and 5.1). Treatment with an appropriate combination regimen should continue after completion of the 24-week delamanid treatment period according to WHO guidelines.

It is recommended that delamanid is administered by directly observed therapy (DOT).

**Posology**

**Adults**

The recommended dose for adults is 100 mg twice daily for 24 weeks.

**Adolescents and children**

Paediatric patients with a body weight of
- $\geq 30$ to $< 50$ kg: the recommended dose is 50 mg twice daily for 24 weeks
- $\geq 50$ kg: the recommended dose is 100 mg twice daily for 24 weeks

For patients with a body weight below 30 kg please see the SmPC for Deltyba 25 mg dispersible tablets.

*Elderly patients (> 65 years of age)*
No data are available in the elderly.

*Renal impairment*
No dose adjustment is considered necessary in patients with mild or moderate renal impairment. There are no data on the use of delamanid in patients with severe renal impairment and its use is not recommended (see sections 4.4 and 5.2).

*Hepatic impairment*
No dose adjustment is considered necessary in patients with mild hepatic impairment. Delamanid is not recommended in patients with moderate to severe hepatic impairment (see sections 4.4 and 5.2).

*Paediatric population*
The safety and efficacy of Deltyba in children with a body weight below 10 kg have not yet been established. Currently available data are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.

*Method of administration*
Oral use.
Delamanid should be taken with food.

4.3 *Contraindications*
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Serum albumin $< 2.8$ g/dL (see section 4.4 regarding use in patients with serum albumin $\geq 2.8$ g/dL).
- Coadministration of medicinal products that are strong inducers of CYP3A4 (e.g. carbamazepine).

4.4 *Special warnings and precautions for use*
There are no data on treatment with delamanid for more than 24 consecutive weeks (see section 4.2).

There are no clinical data on the use of delamanid to treat
- extra pulmonary tuberculosis (e.g. central nervous system, bone)
- infections due to Mycobacterial species other than those of the *M. tuberculosis* complex
- latent infection with *M. tuberculosis*

There are no clinical data on the use of delamanid as part of combination regimens used to treat drug-susceptible *M. tuberculosis*.

*Resistance to delamanid*
Delamanid must only be used in an appropriate combination regimen for MDR-TB treatment as recommended by WHO to prevent development of resistance to delamanid.

*QT prolongation*
QT prolongation has been observed in patients treated with delamanid. This prolongation increases slowly over time in the first 6 to 10 weeks of treatment and remains stable thereafter. QTc prolongation is very closely correlated with the major delamanid metabolite DM-6705. Plasma albumin and
CYP3A4 regulate the formation and metabolism of DM-6705 respectively (see Special Considerations below).

**General recommendations**

It is recommended that electrocardiograms (ECG) should be obtained before initiation of treatment and monthly during the full course of treatment with delamanid. If a QTcF > 500 ms is observed either before the first dose of delamanid or during delamanid treatment, treatment with delamanid should either not be started or should be discontinued. If the QTc interval duration exceeds 450/470 ms for male/female patients during delamanid treatment, these patients should be administered more frequent ECG monitoring. It is also recommended that serum electrolytes, e.g. potassium, are obtained at baseline and corrected if abnormal.

**Special considerations**

**Cardiac risk factors**

Treatment with delamanid should not be initiated in patients with the following risk factors unless the possible benefit of delamanid is considered to outweigh the potential risks. Such patients should receive very frequent monitoring of ECG throughout the full delamanid treatment period.

- Known congenital prolongation of the QTc-interval or any clinical condition known to prolong the QTc interval or QTc > 500 ms.
- History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.
- Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac failure accompanied by reduced left ventricle ejection fraction.
- Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.
- Taking medicinal products that are known to prolong the QTc interval. These include (but are not limited to):
  - Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol).
  - Neuroleptics (e.g. phenothiazines, sertindole, sulotroide, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive agents.
  - Certain antimicrobial agents, including:
    - macrolides (e.g. erythromycin, clarithromycin)
    - moxifloxacin, sparfloxacin (see section 4.4 regarding use with other fluoroquinolones)
    - bedaquiline
    - triazole antifungal agents
    - pentamidine
    - saquinavir
  - Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine).
  - Certain antimalarials with QT-prolonging potential (e.g. halofantrine, quinine, chloroquine, artesunate/amodiaquine, dihydroartemisinin/piperaquine).
  - Cisapride, droperidol, domperidone, bepridil, diphenamid, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide.

**Hypoalbuminaemia**

In a clinical study, the presence of hypoalbuminaemia was associated with an increased risk of prolongation of the QTc interval in delamanid treated patients. Delamanid is contraindicated in patients with albumin < 2.8 g/dL (see section 4.3). Patients who commence delamanid with serum albumin < 3.4 g/dL or experience a fall in serum albumin into this range during treatment should receive very frequent monitoring of ECGs throughout the full delamanid treatment period.

**Co-administration with strong inhibitors of CYP3A4**

Co-administration of delamanid with a strong inhibitor of CYP3A4 (lopinavir/ritonavir) was associated with a 30% higher exposure to the metabolite DM-6705, which has been associated with QTc prolongation. Therefore, if co-administration of delamanid with any strong inhibitor of CYP3A4
is considered necessary it is recommended that there is very frequent monitoring of ECGs, throughout
the full delamanid treatment period.

**Co-administration of delamanid with quinolones**

All QTcF prolongations above 60 ms were associated with concomitant fluoroquinolone use. Therefore, if co-administration is considered to be unavoidable in order to construct an adequate treatment regimen for MDR-TB it is recommended that there is very frequent monitoring of ECGs throughout the full delamanid treatment period.

**Hepatic impairment**

Deltyba is not recommended in patients with moderate to severe hepatic impairment (see sections 4.2
and 5.2).

**Renal impairment**

There are no data on the use of delamanid in patients with severe renal impairment and its use is not recommended (see sections 4.2 and 5.2).

**Excipients**

Deltyba film-coated tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.

### 4.5 Interaction with other medicinal products and other forms of interaction

**Effects of other medicinal products on delamanid**

**Cytochrome P450 3A4 inducers**

Clinical drug-drug interactions studies in healthy subjects indicated a reduced exposure to delamanid, of up to 45% following 15 days of concomitant administration of the strong inducer of cytochrome P450 (CYP) 3A4 (rifampicin 300 mg daily) with delamanid (200 mg daily). No clinically relevant reduction in delamanid exposure was observed with the weak inducer efavirenz when administered at a dose of 600 mg daily for 10 days in combination with delamanid 100 mg twice daily.

**Anti-HIV medicinal products**

In clinical drug-drug interaction studies in healthy subjects, delamanid was administered alone (100 mg twice daily) and with tenofovir disoproxil (245 mg daily) or lopinavir/ritonavir (400/100 mg daily) for 14 days and with efavirenz for 10 days (600 mg daily). Delamanid exposure remained unchanged (< 25% difference) with anti-HIV medicinal products tenofovir disoproxil and efavirenz but was slightly increased with the combination anti-HIV medicinal products containing lopinavir/ritonavir.

**Effects of delamanid on other medicinal products**

**In-vitro studies** showed that delamanid did not inhibit CYP450 isozymes.

**In-vitro studies** showed that delamanid and metabolites did not have any effect on the transporters MDR1(p-gp), BCRP, OATP1, OATP3, OCT1, OCT2, OATP1B1, OATP1B3 and BSEP, at concentrations of approximately 5 to 20-fold greater than the $C_{\text{max}}$ at steady state. However, since the concentrations in the gut can potentially be much greater than these multiples of the $C_{\text{max}}$, there is a potential for delamanid to have an effect on these transporters.

**Anti-tuberculosis medicinal products**

In a clinical drug-drug interaction study in healthy subjects, delamanid was administrated alone (200 mg daily) and with rifampicin/isoniazid/pyrazinamide (300/720/1800 mg daily) or ethambutol (1100 mg daily) for 15 days. Exposure of concomitant anti-TB drugs (rifampicin [R]/ isoniazid [H]/...
pyrazinamide \([Z]\)) was not affected. Co-administration with delamanid significantly increased steady state plasma concentrations of ethambutol by approximately 25%, the clinical relevance is unknown.

**Anti-HIV medicinal products**

In a clinical drug-drug interaction study in healthy subjects, delamanid was administred alone (100 mg twice daily) and tenofovir disoproxil (245 mg daily), lopinavir/ritonavir (400/100 mg daily) for 14 days and with efavirenz for 10 days (600 mg daily). Delamanid given in combination with the anti-HIV-medicines, tenofovir disoproxil, lopinavir/ritonavir and efavirenz, did not affect the exposure to these medicinal products.

**Medicinal products with the potential to prolong QTc**

Care must be taken in using delamanid in patients already receiving medicinal products associated with QT prolongation (see section 4.4). Co-administration of moxifloxacin and delamanid in MDR-TB patients has not been studied. Moxifloxacin is not recommended for use in patients treated with delamanid.

**4.6 Fertility, pregnancy and lactation**

**Pregnancy**

There are no or limited amount of data from the use of delamanid in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Deltyba is not recommended during pregnancy and in women of childbearing potential not using contraception.

**Breast-feeding**

It is unknown whether delamanid/metabolites are excreted in human milk. Available pharmacokinetic/toxicological data in animals have shown excretion of delamanid and/or its metabolites in milk (for details see section 5.3). A risk to the newborns/infants cannot be excluded. It is recommended that women should not breastfeed during treatment with Deltyba.

**Fertility**

Deltyba had no effect on male or female fertility in animals (see section 5.3). There are no clinical data on the effects of delamanid on fertility in humans.

**4.7 Effects on ability to drive and use machines**

Deltyba is expected to have a moderate influence on the ability to drive and use machines. Patients should be advised not to drive or use machines if they experience any adverse reaction with a potential impact on the ability to perform these activities (e.g. headache is very common and tremor is common).

**4.8 Undesirable effects**

**Summary of the safety profile**

The most frequently observed adverse drug reactions in patients treated with delamanid + Optimised Background Regimen (OBR) (i.e. incidence > 10%) are nausea (32.9%), vomiting (29.9%), headache (28.4%), sleep disorders and disturbances (28.2%), dizziness (22.4%), gastritis (15.9%) and decreased appetite (13.1%).

**Tabulated list of adverse reactions**

The list of adverse drug reactions and frequencies are based on the results from 2 double-blind placebo controlled clinical trials. The adverse drug reactions are listed by MedDRA System Organ Class and
Preferred Term. Within each System Organ Class, adverse reactions are listed under frequency categories of very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/1 000 to < 1/1 000), very rare (< 1/10 000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table: Adverse drug reactions to delamanid

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Frequency very common</th>
<th>Frequency common</th>
<th>Frequency uncommon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endocrine disorders</td>
<td>-</td>
<td>Hypothyroidisma</td>
<td>-</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Decreased appetite</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Sleep disorders and disturbancesb</td>
<td>Psychotic disorderc Anxietyd Depressione Hallucinationf</td>
<td>-</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Dizziness</td>
<td>Hypoaesthesia Tremor</td>
<td>Lethargy</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>-</td>
<td>Atrioventricular block first degree Ventricular extrasystoles Palpitations</td>
<td>-</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>-</td>
<td>Throat irritation</td>
<td>-</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Nausea Vomiting Gastritisb</td>
<td>Dyspepsia</td>
<td>-</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>-</td>
<td>Muscular weakness Muscle spasms</td>
<td>-</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>-</td>
<td>Chest pain</td>
<td>-</td>
</tr>
<tr>
<td>Investigations</td>
<td>-</td>
<td>Cortisol increasedi Electrocardiogram QT prolonged</td>
<td>-</td>
</tr>
</tbody>
</table>

Event terms that represent the same medical concept or condition were grouped together and reported as a single adverse drug reaction in Table ‘Adverse drug reactions to delamanid’. Preferred terms actually reported in the double-blind clinical trials and contributing to the relevant adverse drug reaction are indicated in parentheses, as listed below:

a. Hypothyroidism (hypothyroidism, primary hypothyroidism)
b. Sleep disorders and disturbances (initial insomnia, insomnia, sleep disorder)
c. Psychotic disorder (acute psychosis, psychotic disorder, reactive psychosis, substance-induced psychotic disorder)
d. Anxiety (anxiety, anxiety disorder, generalised anxiety disorder)
e. Depression (adjustment disorder with depressed mood, depressed mood, depression, major depression, mixed anxiety and depressive disorder, persistent depressive disorder, schizoaffective disorder depressive type)
f. Hallucination (hallucination; hallucination, auditory; hallucination, visual; hallucination tactile; hallucination mixed; hypnopompic hallucination; hypnagogic hallucination)
g. Headache (head discomfort, headache, migraine, sinus headache, tension headache, vascular headache)
h. Gastritis (chronic gastritis, gastritis, gastritis erosive)
i. Cortisol increased (Cushing’s syndrome, hyperadrenocorticism, cortisol increased)
Description of selected adverse reactions

**ECG QT interval prolongation**

In patients receiving 200 mg delamanid total daily dose in the phase 2 and 3 trials, the mean placebo corrected increase in QTcF from baseline ranged from 4.7 - 7.6 ms at 1 month and 5.3 ms - 12.1 ms at 2 months, respectively. The incidence of a QTcF interval > 500 ms ranged from 0.6% (1/161) - 2.1% (7/341) in patients receiving delamanid 200 mg total daily dose versus 0% (0/160) - 1.2% (2/170) of patients receiving placebo + OBR, while the incidence of QTcF change from baseline > 60 ms ranged from 3.1% (5/161) - 10.3% (35/341) in patients receiving delamanid 200 mg total daily dose versus 0% (0/160) - 7.1% (12/170) in patients receiving placebo.

**Palpitations**

For patients receiving delamanid + OBR in the phase 2 and 3 trials, the frequency was 7.9% (frequency category common) in comparison to a frequency of 6.7% in patients receiving placebo + OBR.

**Paediatric population**

Based on a study (see section 5.1) in 37 paediatric patients aged 0 to 17 years, the frequency, type and severity of adverse reactions in children are expected to be the same as in adults. Cases of hallucination have been reported predominantly in the paediatric population during post-marketing. The incidence of hallucination in clinical trials was common for children (5.4%) and adults (1%).

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

**4.9 Overdose**

No cases of delamanid overdose have been observed in clinical trials. However, additional clinical data showed that in patients receiving 200 mg twice daily, i.e. total 400 mg delamanid per day, the overall safety profile is comparable to that in patients receiving the recommended dose of 100 mg twice daily. Albeit, some reactions were observed at a higher frequency and the rate of QT prolongation increased in a dose-related manner. Treatment of overdose should involve immediate measures to remove delamanid from the gastrointestinal tract and supportive care as required. Frequent ECG monitoring should be performed.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Antimycobacterials, drugs for treatment of tuberculosis, ATC code: J04AK06.

**Mechanism of action**

The pharmacological mode of action of delamanid involves inhibition of the synthesis of the mycobacterial cell wall components, methoxy- mycolic and keto-mycolic acid. The identified metabolites of delamanid do not show anti-mycobacterial activity.

**Activity against specific pathogens**
Delamanid has no in vitro activity against bacterial species other than mycobacteria.

Resistance

Mutation in one of the 5 coenzyme F420 genes is suggested as the mechanism for resistance against delamanid in mycobacteria. In mycobacteria, the in vitro frequencies of spontaneous resistance to delamanid were similar to those for isoniazid and were higher than those for rifampicin. Resistance to delamanid has been documented to occur during treatment (see section 4.4). Delamanid does not show cross-resistance with any of the currently used anti-tuberculosis medicinal products except pretomanid. In vitro studies have shown cross-resistance with pretomanid. This is likely to be due to delamanid and pretomanid being activated via the same pathway.

Susceptibility testing interpretive criteria

When 7H11 agar medium is used for drug susceptibility testing, the recommended epidemiological cut-off (ECOFF) and susceptibility testing interpretive criteria for delamanid are:

ECOFF: 0.016 mg/L
Clinical breakpoint: S \leq 0.016 mg/L; R > 0.016 mg/L
S = susceptible; R = resistant

Data from clinical studies

Delamanid has been evaluated in two, double-blind, placebo-controlled trials for the treatment of MDR-TB. The analyses of SCC were conducted on the modified intent to treat population which included patients who had positive cultures at baseline and the isolate was resistant to both isoniazid and rifampicin, i.e., had MDR-TB.

In the first trial (Trial 204), 64/141 (45.4%) patients randomised to receive delamanid 100 mg BID + OBR and 37/125 (29.6%) of patients randomised to receive placebo (PLC) + OBR achieved two-month sputum culture conversion (SCC) (i.e. growth of Mycobacterium tuberculosis to no growth over the first 2 months and maintained for 1 more month) (p = 0.0083). The time to SCC for the group randomised to 100 mg BID was also found to be faster than for the group randomised to receive placebo + OBR (p = 0.0056).

In the second trial (Trial 213), delamanid was administered orally at 100 mg BID as an add-on therapy to an OBR for 2 months followed by 200 mg once daily for 4 months. The median time to SCC was 51 days in the delamanid + OBR group compared with 57 days in the PLC + OBR group (p = 0.0562 using the stratified modified Peto-Peto modification of Gehan’s Wilcoxon rank sum test). The proportion of patients achieving SCC (sputum culture conversion) after the 6-month treatment period was 87.6% (198/226) in the delamanid + OBR treatment group compared to 86.1% (87/101) in the placebo + OBR treatment group (p = 0.7131).

All missing cultures up to the time of SCC were assumed to be positive cultures in the primary analysis. Two sensitivity analyses were conducted - a last-observation-carried-forward (LOCF) analysis and an analysis using ‘bookending’ methodology (which required that the previous and subsequent cultures were both observed negative cultures to impute a negative result, otherwise a positive result was imputed). Both showed a 13-day shorter median time to SCC in the delamanid + OBR group (p = 0.0281 for LOCF and p = 0.0052 for ‘bookending’).

Delamanid resistance (defined as MIC \geq 0.2 \mu g/mL) has been observed at baseline in 2 of 316 patients in Trial 204 and 2 of 511 patients in Trial 213 (4 of 827 patients [0.48%]). Delamanid resistance emerged in 4 of 341 patients (1.2%) randomised to receive delamanid for 6 months in Trial 213. These four patients were only receiving two other medicinal products in addition to delamanid.

Paediatric population

The pharmacokinetics, safety and efficacy of delamanid in combination with a background regimen (BR) were evaluated in trial 242-12 -232 (10 days pharmacokinetics) followed by trial -233
(pharmacokinetics, efficacy and safety), both single-arm, open-label trials, which included 37 patients who had a median age of 4.55 years (range 0.78 to 17.60 years), 25 (67.6%) were Asian and 19 (51.4%) were female.
Paediatric patients were enrolled in four groups:
Group 1: 12 to 17 years (7 patients), group 2: 6 to 11 years (6 patients), group 3: 3 to 5 years (12 patients) and group 4: 0 to 2 years (12 patients). The overall mean baseline body weight of subjects was 19.5 kg and in groups 1, 2, 3, and 4 the mean body weights were 38.4, 25.1, 14.8, and 10.3 kg, respectively.

The patients had confirmed or probable MDR-TB infection and were to complete 26 weeks of treatment with delamanid + OBR, followed by OBR only in accordance with the WHO recommendation. Patients in groups 1 and 2 received film-coated tablets. The delamanid dose in group 1 was 100 mg twice daily and 50 mg twice daily in group 2. The doses administered were higher than the currently recommended weight-based dosage in the paediatric population. Patients in groups 3 and 4 received dispersible tablets. This paediatric formulation is not bio-equivalent with the film-coated tablets. Patients in group 3 were administered 25 mg twice daily and patients in group 4 were administered doses between 10 mg twice daily and 5 mg once daily based on body weight. The doses administered in group 4 were below the currently recommended weight-based dosage in the paediatric population.

A population PK analysis was performed on data from the 2 paediatric trials to determine the doses in paediatric subjects which would provide delamanid exposures similar to those observed in adult subjects with MDR-TB. Data in children with a body weight of less than 10 kg were too limited to determine doses for that patient population.

This medicinal product has been authorised under a so-called ‘conditional approval’ scheme. This means that further evidence on this medicinal product is awaited. The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.

5.2 Pharmacokinetic properties

Absorption

Oral bioavailability of delamanid improves when administered with a standard meal, by about 2.7-fold compared to fasting conditions. The peak plasma concentrations are reached in approximately 4 hours post-dose, regardless of food intake.

Distribution

Delamanid highly binds to all plasma proteins with a binding to total proteins of ≥ 99.5%. Delamanid has a large apparent volume of distribution (Vz/F of 2 100 L).

Biotransformation

Delamanid is primarily metabolised in plasma by albumin and to a lesser extent by CYP3A4. The complete metabolic profile of delamanid has not yet been elucidated, and there is a potential for drug interactions with other co-administered medicinal products, if significant unknown metabolites are discovered. The identified metabolites do not show anti-mycobacterial activity but some contribute to QTc prolongation, mainly DM-6705. Concentrations of the identified metabolites progressively increase to steady state after 6 to 10 weeks.

Elimination

Delamanid disappears from plasma with a t1/2 of 30 to 38 hours. Delamanid is not excreted in urine.

Linearity/non-linearity
Delamanid plasma exposure increases less than proportionally with increasing dose.

Special populations

Paediatric population
During treatment with the recommended delamanid doses to adolescents and children with a body weight of at least 10 kg (see section 4.2), similar plasma exposure were obtained as in adults.

Patients with renal impairment
Less than 5% of an oral dose of delamanid is recovered from urine. Mild renal impairment (50 mL/min < CrCLN < 80 mL/min) does not appear to affect delamanid exposure. Therefore no dose adjustment is needed for patients with mild or moderate renal impairment. It is not known whether delamanid and metabolites will be significantly removed by haemodialysis or peritoneal dialysis.

Patients with hepatic impairment
No dose adjustment is considered necessary for patients with mild hepatic impairment. Delamanid is not recommended in patients with moderate to severe hepatic impairment.

Elderly patients (≥ 65 years)
No patients of ≥ 65 years of age were included in clinical trials.

5.3 Preclinical safety data

Non-clinical data reveal no specific hazard for humans based on conventional studies for genotoxicity and carcinogenic potential. Delamanid and/or its metabolites have the potential to affect cardiac repolarisation via blockade of hERG potassium channels. In the dog, foamy macrophages were observed in lymphoid tissue of various organs during repeat-dose toxicity studies. The finding was shown to be partially reversible; the clinical relevance of this finding is unknown. Repeat-dose toxicity studies in rabbits revealed an inhibitory effect of delamanid and/or its metabolites on vitamin K-dependent blood clotting. In rabbits reproductive studies, embryo-fetal toxicity was observed at maternally toxic dosages. Pharmacokinetic data in animals have shown excretion of delamanid/metabolites into breast milk. In lactating rats, the Cmax for delamanid in breast milk was 4-fold higher than that of the blood. In juvenile toxicity studies in rats, all delamanid treatment-related findings were consistent with those noted in adult animals.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core
Hypromellose phthalate
Povidone
all-rac-α-Tocopherol
Cellulose, microcrystalline
Sodium starch glycolate (type A)
Carmellose calcium
Silica, colloidal hydrated
Magnesium stearate
Lactose monohydrate

Film coating
Hypromellose
Macrogol 8000
Titanium dioxide
Talc
Iron oxide yellow (E172)
6.2 Incompatibilities

Not applicable.

6.3 Shelf life

5 years

6.4 Special precautions for storage

Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

Aluminium/Aluminium blister:
48 tablets.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Otsuka Novel Products GmbH
Erika-Mann-Straße 21
80636 München
Germany

8. MARKETING AUTHORIZAtION NUMBER(S)

EU/1/13/875/004

9. DATE OF FIRST AUTHORIZATION/RENEWAL OF THE AUTHORIZATION

Date of first authorisation: 28 April 2014
Date of latest renewal: 24 March 2023

10. DATE OF REVISION OF THE TEXT

<{MM/YYYY}>

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. **NAME OF THE MEDICINAL PRODUCT**

Deltyba 25 mg dispersible tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each dispersible tablet contains 25 mg delamanid.

For the full list of excipients, see section 6.1.

3. **PHARMACEUTICAL FORM**

Dispersible tablet

Round, white to off-white dispersible tablet, 11 mm in diameter, debossed with ‘DLM’ and ‘25’ on one side.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4.2, 4.4 and 5.1).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

4.2 **Posology and method of administration**

Treatment with delamanid should be initiated and monitored by a physician experienced in the management of multidrug-resistant *Mycobacterium tuberculosis*.

Delamanid must always be administered as part of an appropriate combination regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) (see sections 4.4 and 5.1). Treatment with an appropriate combination regimen should continue after completion of the 24-week delamanid treatment period according to WHO guidelines.

It is recommended that delamanid is administered by directly observed therapy (DOT).

**Posology**

**Adults**

For adult patients the use of film-coated tablets is recommended, please see the SmPC for Deltyba 50 mg film-coated tablets.

**Adolescents, children and infants**

Paediatric patients with a body weight of
- \( \geq 10 \text{ to } < 20 \text{ kg} \): the recommended dose is 25 mg twice daily for 24 weeks
- \( \geq 20 \) to \(< 30 \) kg: the recommended dose is 50 mg every morning and 25 mg every evening for 24 weeks

For patients with a body weight of 30 kg or more please see the SmPC for Deltyba 50 mg film-coated tablets.

**Elderly patients (\( > 65 \) years of age)**
No data are available in the elderly. For adult patients please see the SmPC for Deltyba 50 mg film-coated tablets.

**Renal impairment**
No dose adjustment is considered necessary in patients with mild or moderate renal impairment. There are no data on the use of delamanid in patients with severe renal impairment and its use is not recommended (see sections 4.4 and 5.2).

**Hepatic impairment**
No dose adjustment is considered necessary in patients with mild hepatic impairment. Delamanid is not recommended in patients with moderate to severe hepatic impairment (see sections 4.4 and 5.2).

**Paediatric population**
The safety and efficacy of Deltyba in children with a body weight below 10 kg have not yet been established. Currently available data are described in sections 4.8, 5.1 and 5.2 but no recommendation on a posology can be made.

**Method of administration**

Oral use.
Delamanid should be taken with food.

The dispersible tablets must be dispersed in water using 10 to 15 mL per 25 mg dispersible tablet and the resulting whitish suspension must be ingested immediately. Thereafter further 10 to 15 mL of water per dispersible tablet must be added to the glass or cup to ensure that potentially remaining suspension is dispersed and the resulting suspension must also be ingested.

### 4.3 Contraindications

- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Serum albumin \(< 2.8 \) g/dL (see section 4.4 regarding use in patients with serum albumin \( \geq 2.8 \) g/dL).
- Coadministration of medicinal products that are strong inducers of CYP3A4 (e.g. carbamazepine).

### 4.4 Special warnings and precautions for use

There are no data on treatment with delamanid for more than 24 consecutive weeks (see section 4.2).

There are no clinical data on the use of delamanid to treat
- extra pulmonary tuberculosis (e.g. central nervous system, bone)
- infections due to Mycobacterial species other than those of the *M. tuberculosis* complex
- latent infection with *M. tuberculosis*

There are no clinical data on the use of delamanid as part of combination regimens used to treat drug-susceptible *M. tuberculosis*.
Resistance to delamanid

Delamanid must only be used in an appropriate combination regimen for MDR-TB treatment as recommended by WHO to prevent development of resistance to delamanid.

QT prolongation

QT prolongation has been observed in patients treated with delamanid. This prolongation increases slowly over time in the first 6 to 10 weeks of treatment and remains stable thereafter. QTc prolongation is very closely correlated with the major delamanid metabolite DM-6705. Plasma albumin and CYP3A4 regulate the formation and metabolism of DM-6705 respectively (see Special Considerations below).

General recommendations

It is recommended that electrocardiograms (ECG) should be obtained before initiation of treatment and monthly during the full course of treatment with delamanid. If a QTcF > 500 ms is observed either before the first dose of delamanid or during delamanid treatment, treatment with delamanid should either not be started or should be discontinued. If the QTc interval duration exceeds 450/470 ms for male/female patients during delamanid treatment, these patients should be administered more frequent ECG monitoring. It is also recommended that serum electrolytes, e.g. potassium, are obtained at baseline and corrected if abnormal.

Special considerations

Cardiac risk factors

Treatment with delamanid should not be initiated in patients with the following risk factors unless the possible benefit of delamanid is considered to outweigh the potential risks. Such patients should receive very frequent monitoring of ECG throughout the full delamanid treatment period.
- Known congenital prolongation of the QTc-interval or any clinical condition known to prolong the QTc interval or QTc > 500 ms.
- History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.
- Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac failure accompanied by reduced left ventricle ejection fraction.
- Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.
- Taking medicinal products that are known to prolong the QTc interval. These include (but are not limited to):
  - Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol).
  - Neuroleptics (e.g. phenothiazines, sertindole, sulfotride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive agents.
  - Certain antimicrobial agents, including:
    - macrodides (e.g. erythromycin, clarithromycin)
    - moxifloxacin, sparfloxacin (see section 4.4 regarding use with other fluoroquinolones)
  - bedaquiline
  - triazole antifungal agents
  - pentamidine
    - saquinavir
  - Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine).
  - Certain antimalarials with QT-prolonging potential (e.g. halofantrine, quinine, chloroquine, artesunate/amodiaquine, dihydroartemisinin/piperaquine).
  - Cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide.

Hypoalbuminaemia
In a clinical study, the presence of hypoalbuminaemia was associated with an increased risk of prolongation of the QTc interval in delamanid treated patients. Delamanid is contraindicated in patients with albumin < 2.8 g/dL (see section 4.3). Patients who commence delamanid with serum albumin < 3.4 g/dL or experience a fall in serum albumin into this range during treatment should receive very frequent monitoring of ECGs throughout the full delamanid treatment period.

Co-administration with strong inhibitors of CYP3A4
Co-administration of delamanid with a strong inhibitor of CYP3A4 (lopinavir/ritonavir) was associated with a 30% higher exposure to the metabolite DM-6705, which has been associated with QTc prolongation. Therefore, if co-administration of delamanid with any strong inhibitor of CYP3A4 is considered necessary it is recommended that there is very frequent monitoring of ECGs, throughout the full delamanid treatment period.

Co-administration of delamanid with quinolones
All QTcF prolongations above 60 ms were associated with concomitant fluoroquinolone use. Therefore, if co-administration is considered to be unavoidable in order to construct an adequate treatment regimen for MDR-TB it is recommended that there is very frequent monitoring of ECGs throughout the full delamanid treatment period.

Hepatic impairment
Deltbyba is not recommended in patients with moderate to severe hepatic impairment (see sections 4.2 and 5.2).

Renal impairment
There are no data on the use of delamanid in patients with severe renal impairment and its use is not recommended (see sections 4.2 and 5.2).

4.5 Interaction with other medicinal products and other forms of interaction

Effects of other medicinal products on delamanid

Cytochrome P450 3A4 inducers
Clinical drug-drug interactions studies in healthy subjects indicated a reduced exposure to delamanid, of up to 45% following 15 days of concomitant administration of the strong inducer of cytochrome P450 (CYP) 3A4 (rifampicin 300 mg daily) with delamanid (200 mg daily). No clinically relevant reduction in delamanid exposure was observed with the weak inducer efavirenz when administered at a dose of 600 mg daily for 10 days in combination with delamanid 100 mg twice daily.

Anti-HIV medicinal products
In clinical drug-drug interaction studies in healthy subjects, delamanid was administered alone (100 mg twice daily) and with tenofovir disoproxil (245 mg daily) or lopinavir/ritonavir (400/100 mg daily) for 14 days and with efavirenz for 10 days (600 mg daily). Delamanid exposure remained unchanged (< 25% difference) with anti-HIV medicinal products tenofovir disoproxil and efavirenz but was slightly increased with the combination anti-HIV medicinal products containing lopinavir/ritonavir.

Effects of delamanid on other medicinal products

In-vitro studies showed that delamanid did not inhibit CYP450 isozymes.

In-vitro studies showed that delamanid and metabolites did not have any effect on the transporters MDR1 (p-gp), BCRP, OATP1, OATP3, OCT1, OCT2, OATP1B1, OATP1B3 and BSEP, at concentrations of approximately 5 to 20-fold greater than the C\text{max} at steady state. However, since the concentrations in the gut can potentially be much greater than these multiples of the C\text{max}, there is a potential for delamanid to have an effect on these transporters.
Anti-tuberculosis medicinal products
In a clinical drug-drug interaction study in healthy subjects, delamanid was administered alone (200 mg daily) and with rifampicin/isoniazid/pyrazinamide (300/720/1800 mg daily) or ethambutol (1100 mg daily) for 15 days. Exposure of concomitant anti-TB drugs (rifampicin [R]/isoniazid [H]/pyrazinamide [Z]) was not affected. Co-administration with delamanid significantly increased steady state plasma concentrations of ethambutol by approximately 25%, the clinical relevance is unknown.

Anti-HIV medicinal products
In a clinical drug-drug interaction study in healthy subjects, delamanid was administered alone (100 mg twice daily) and tenofovir disoproxil (245 mg daily), lopinavir/ritonavir (400/100 mg daily) for 14 days and with efavirenz for 10 days (600 mg daily). Delamanid given in combination with the anti-HIV-medicines, tenofovir disoproxil, lopinavir/ritonavir and efavirenz, did not affect the exposure to these medicinal products.

Medicinal products with the potential to prolong QTc
Care must be taken in using delamanid in patients already receiving medicinal products associated with QT prolongation (see section 4.4). Co-administration of moxifloxacin and delamanid in MDR-TB patients has not been studied. Moxifloxacin is not recommended for use in patients treated with delamanid.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no or limited amount of data from the use of delamanid in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). Deltyba is not recommended during pregnancy and in women of childbearing potential not using contraception.

Breast-feeding

It is unknown whether delamanid/metabolites are excreted in human milk. Available pharmacokinetic/toxicological data in animals have shown excretion of delamanid and/or its metabolites in milk (for details see section 5.3). A risk to the newborns/infants cannot be excluded. It is recommended that women should not breastfeed during treatment with Deltyba.

Fertility

Deltyba had no effect on male or female fertility in animals (see section 5.3). There are no clinical data on the effects of delamanid on fertility in humans.

4.7 Effects on ability to drive and use machines

Deltyba is expected to have a moderate influence on the ability to drive and use machines. Patients should be advised not to drive or use machines if they experience any adverse reaction with a potential impact on the ability to perform these activities (e.g. headache is very common and tremor is common).

4.8 Undesirable effects

Summary of the safety profile

The most frequently observed adverse drug reactions in patients treated with delamanid + Optimised Background Regimen (OBR) (i.e. incidence > 10%) are nausea (32.9%), vomiting (29.9%), headache (28.4%), sleep disorders and disturbances (28.2%), dizziness (22.4%), gastritis (15.9%) and decreased appetite (13.1%).
Tabulated list of adverse reactions

The list of adverse drug reactions and frequencies are based on the results from 2 double-blind placebo controlled clinical trials. The adverse drug reactions are listed by MedDRA System Organ Class and Preferred Term. Within each System Organ Class, adverse reactions are listed under frequency categories of very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1 000 to < 1/100), rare (≥ 1/10 000 to < 1/1 000), very rare (< 1/10 000) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

Table: Adverse drug reactions to delamanid

<table>
<thead>
<tr>
<th>System Organ Class</th>
<th>Frequency very common</th>
<th>Frequency common</th>
<th>Frequency uncommon</th>
</tr>
</thead>
<tbody>
<tr>
<td>Endocrine disorders</td>
<td>-</td>
<td>Hypothyroidism&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-</td>
</tr>
<tr>
<td>Metabolism and nutrition disorders</td>
<td>Decreased appetite</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>Sleep disorders and disturbances&lt;sup&gt;b&lt;/sup&gt;</td>
<td>Psychotic disorder&lt;sup&gt;c&lt;/sup&gt; Anxiety&lt;sup&gt;d&lt;/sup&gt; Depression&lt;sup&gt;e&lt;/sup&gt; Hallucination&lt;sup&gt;f&lt;/sup&gt;</td>
<td>-</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Dizziness Headache&lt;sup&gt;g&lt;/sup&gt;</td>
<td>Hypoaesthesia Tremor</td>
<td>Lethargy</td>
</tr>
<tr>
<td>Cardiac disorders</td>
<td>-</td>
<td>Atroventricular block first degree Ventricular extrasystoles Palpitations</td>
<td>-</td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>-</td>
<td>Throat irritation</td>
<td>-</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Nausea Vomiting Gastritis&lt;sup&gt;h&lt;/sup&gt;</td>
<td>Dyspepsia</td>
<td>-</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td>-</td>
<td>Muscular weakness Muscle spasms</td>
<td>-</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>-</td>
<td>Chest pain</td>
<td>-</td>
</tr>
<tr>
<td>Investigations</td>
<td>-</td>
<td>Cortisol increased Electrocardiogram QT prolonged</td>
<td>-</td>
</tr>
</tbody>
</table>

Event terms that represent the same medical concept or condition were grouped together and reported as a single adverse drug reaction in Table ‘Adverse drug reactions to delamanid’. Preferred terms actually reported in the double-blind clinical trials and contributing to the relevant adverse drug reaction are indicated in parentheses, as listed below:

a. Hypothyroidism (hypothyroidism, primary hypothyroidism)
b. Sleep disorders and disturbances (initial insomnia, insomnia, sleep disorder)
c. Psychotic disorder (acute psychosis, psychotic disorder, reactive psychosis, substance-induced psychotic disorder)
d. Anxiety (anxiety, anxiety disorder, generalised anxiety disorder)
e. Depression (adjustment disorder with depressed mood, depressed mood, depression, major depression, mixed anxiety and depressive disorder, persistent depressive disorder, schizoaffective disorder depressive type)
f. Hallucination (hallucination; hallucination, auditory; hallucination, visual; hallucination tactile; hallucination mixed; hypnopompic hallucination; hypnagogic hallucination)
g. Headache (head discomfort, headache, migraine, sinus headache, tension headache, vascular headache)
h. Gastritis (chronic gastritis, gastritis, gastritis erosive)
i. Cortisol increased (Cushing’s syndrome, hyperadrenocorticism, cortisol increased)

Description of selected adverse reactions

ECG QT interval prolongation
In patients receiving 200 mg delamanid total daily dose in the phase 2 and 3 trials, the mean placebo corrected increase in QTcF from baseline ranged from 4.7 - 7.6 ms at 1 month and 5.3 ms - 12.1 ms at 2 months, respectively. The incidence of a QTcF interval > 500 ms ranged from 0.6% (1/161) - 2.1% (7/341) in patients receiving delamanid 200 mg total daily dose versus 0% (0/160) - 1.2% (2/170) of patients receiving placebo + OBR, while the incidence of QTcF change from baseline > 60 ms ranged from 3.1% (5/161) - 10.3% (35/341) in patients receiving delamanid 200 mg total daily dose versus 0% (0/160) - 7.1% (12/170) in patients receiving placebo.

Palpitations
For patients receiving delamanid + OBR in the phase 2 and 3 trials, the frequency was 7.9% (frequency category common) in comparison to a frequency of 6.7% in patients receiving placebo + OBR.

Paediatric population
Based on a study (see section 5.1) in 37 paediatric patients aged 0 to 17 years, the frequency, type and severity of adverse reactions in children are expected to be the same as in adults. Cases of hallucination have been reported predominantly in the paediatric population during post-marketing. The incidence of hallucination in clinical trials was common for children (5.4%) and adults (1%).

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose
No cases of delamanid overdose have been observed in clinical trials. However, additional clinical data showed that in patients receiving 200 mg twice daily, i.e. total 400 mg delamanid per day, the overall safety profile is comparable to that in patients receiving the recommended dose of 100 mg twice daily. Albeit, some reactions were observed at a higher frequency and the rate of QT prolongation increased in a dose-related manner. Treatment of overdose should involve immediate measures to remove delamanid from the gastrointestinal tract and supportive care as required. Frequent ECG monitoring should be performed.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties
Pharmacotherapeutic group: Antimycobacterials, drugs for treatment of tuberculosis, ATC code: J04AK06.

Mechanism of action
The pharmacological mode of action of delamanid involves inhibition of the synthesis of the mycobacterial cell wall components, methoxy-mycolic and keto-mycolic acid. The identified metabolites of delamanid do not show anti-mycobacterial activity.

Activity against specific pathogens

Delamanid has no \textit{in vitro} activity against bacterial species other than mycobacteria.

Resistance

Mutation in one of the 5 coenzyme F420 genes is suggested as the mechanism for resistance against delamanid in mycobacteria. In mycobacteria, the \textit{in vitro} frequencies of spontaneous resistance to delamanid were similar to those for isoniazid and were higher than those for rifampicin. Resistance to delamanid has been documented to occur during treatment (see section 4.4). Delamanid does not show cross-resistance with any of the currently used anti-tuberculosis medicinal products except pretomanid. \textit{In vitro} studies have shown cross-resistance with pretomanid. This is likely to be due to delamanid and pretomanid being activated via the same pathway.

Susceptibility testing interpretive criteria

When 7H11 agar medium is used for drug susceptibility testing, the recommended epidemiological cut-off (ECOFF) and susceptibility testing interpretive criteria for delamanid are:

\textbf{ECOFF:} $0.016 \text{ mg/L}$

Clinical breakpoint: $S \leq 0.016 \text{ mg/L}; R > 0.016 \text{ mg/L}$

S = susceptible; R = resistant

Data from clinical studies

Delamanid has been evaluated in two, double-blind, placebo-controlled trials for the treatment of MDR-TB. The analyses of SCC were conducted on the modified intent to treat population which included patients who had positive cultures at baseline and the isolate was resistant to both isoniazid and rifampicin, i.e., had MDR-TB.

In the first trial (Trial 204), 64/141 (45.4\%) patients randomised to receive delamanid 100 mg BID + OBR and 37/125 (29.6\%) of patients randomised to receive placebo (PLC) + OBR achieved two-month sputum culture conversion (SCC) (i.e. growth of \textit{Mycobacterium tuberculosis} to no growth over the first 2 months and maintained for 1 more month) ($p = 0.0083$). The time to SCC for the group randomised to 100 mg BID was also found to be faster than for the group randomised to receive placebo + OBR ($p = 0.0056$).

In the second trial (Trial 213), delamanid was administered orally at 100 mg BID as an add-on therapy to an OBR for 2 months followed by 200 mg once daily for 4 months. The median time to SCC was 51 days in the delamanid + OBR group compared with 57 days in the PLC + OBR group ($p = 0.0562$ using the stratified modified Peto-Peto modification of Gehan’s Wilcoxon rank sum test). The proportion of patients achieving SCC (sputum culture conversion) after the 6-month treatment period was 87.6\% (198/226) in the delamanid + OBR treatment group compared to 86.1\% (87/101) in the placebo + OBR treatment group ($p = 0.7131$). All missing cultures up to the time of SCC were assumed to be positive cultures in the primary analysis. Two sensitivity analyses were conducted - a last-observation-carried-forward (LOCF) analysis and an analysis using ‘bookending’ methodology (which required that the previous and subsequent cultures were both observed negative cultures to impute a negative result, otherwise a positive result was imputed). Both showed a 13-day shorter median time to SCC in the delamanid + OBR group ($p = 0.0281$ for LOCF and $p = 0.0052$ for ‘bookending’).

Delamanid resistance (defined as MIC $\geq 0.2 \mu g/mL$) has been observed at baseline in 2 of 316 patients in Trial 204 and 2 of 511 patients in Trial 213 (4 of 827 patients [0.48\%]). Delamanid resistance
emerged in 4 of 341 patients (1.2%) randomised to receive delamanid for 6 months in Trial 213. These four patients were only receiving two other medicinal products in addition to delamanid.

**Paediatric population**

The pharmacokinetics, safety and efficacy of delamanid in combination with a background regimen (BR) were evaluated in trial 242-12 -232 (10 days pharmacokinetics) followed by trial -233 (pharmacokinetics, efficacy and safety), both single-arm, open-label trials, which included 37 patients who had a median age of 4.55 years (range 0.78 to 17.60 years), 25 (67.6%) were Asian and 19 (51.4%) were female.

Paediatric patients were enrolled in four groups:
- Group 1: 12 to 17 years (7 patients)
- Group 2: 6 to 11 years (6 patients)
- Group 3: 3 to 5 years (12 patients)
- Group 4: 0 to 2 years (12 patients)

The overall mean baseline body weight of subjects was 19.5 kg and in groups 1, 2, 3, and 4 the mean body weights were 38.4, 25.1, 14.8, and 10.3 kg, respectively.

The patients had confirmed or probable MDR-TB infection and were to complete 26 weeks of treatment with delamanid + OBR, followed by OBR only in accordance with the WHO recommendation. Patients in groups 1 and 2 received film-coated tablets. The delamanid dose in group 1 was 100 mg twice daily and 50 mg twice daily in group 2. The doses administered were higher than the currently recommended weight-based dosage in the paediatric population. Patients in groups 3 and 4 received dispersible tablets. This paediatric formulation is not bio-equivalent with the film-coated tablets. Patients in group 3 were administered 25 mg twice daily and patients in group 4 were administered doses between 10 mg twice daily and 5 mg once daily based on body weight. The doses administered in group 4 were below the currently recommended weight-based dosage in the paediatric population.

A population PK analysis was performed on data from the 2 paediatric trials to determine the doses in paediatric subjects which would provide delamanid exposures similar to those observed in adult subjects with MDR-TB. Data in children with a body weight of less than 10 kg were too limited to determine doses for that patient population.

This medicinal product has been authorised under a so-called ‘conditional approval’ scheme. This means that further evidence on this medicinal product is awaited. The European Medicines Agency will review new information on this medicinal product at least every year and this SmPC will be updated as necessary.

**5.2 Pharmacokinetic properties**

**Absorption**

Oral bioavailability of delamanid improves when administered with a standard meal, by about 2.7-fold compared to fasting conditions. The peak plasma concentrations are reached in approximately 5 hours post-dose, regardless of food intake.

**Distribution**

Delamanid highly binds to all plasma proteins with a binding to total proteins of ≥99.5%. Delamanid has a large apparent volume of distribution (Vz/F of 2 100 L).

**Biotransformation**

Delamanid is primarily metabolised in plasma by albumin and to a lesser extent by CYP3A4. The complete metabolic profile of delamanid has not yet been elucidated, and there is a potential for drug interactions with other co-administered medicinal products, if significant unknown metabolites are discovered. The identified metabolites do not show anti-mycobacterial activity but some contribute to QTc prolongation, mainly DM-6705. Concentrations of the identified metabolites progressively increase to steady state after 6 to 10 weeks.
Elimination

Delamanid disappears from plasma with a $t_{1/2}$ of 30 to 38 hours. Delamanid is not excreted in urine.

Linearity/non-linearity

Delamanid plasma exposure increases less than proportionally with increasing dose.

Special populations

Paediatric population

During treatment with the recommended delamanid doses to adolescents and children with a body weight of at least 10 kg (see section 4.2), similar plasma exposure were obtained as in adults.

Patients with renal impairment

Less than 5% of an oral dose of delamanid is recovered from urine. Mild renal impairment ($50 \text{ mL/min} < \text{CrCLN} < 80 \text{ mL/min}$) does not appear to affect delamanid exposure. Therefore no dose adjustment is needed for patients with mild or moderate renal impairment. It is not known whether delamanid and metabolites will be significantly removed by haemodialysis or peritoneal dialysis.

Patients with hepatic impairment

No dose adjustment is considered necessary for patients with mild hepatic impairment. Delamanid is not recommended in patients with moderate to severe hepatic impairment.

Elderly patients (≥ 65 years)

No patients of ≥ 65 years of age were included in clinical trials.

5.3 Preclinical safety data

Non-clinical data reveal no specific hazard for humans based on conventional studies for genotoxicity and carcinogenic potential. Delamanid and/or its metabolites have the potential to affect cardiac repolarisation via blockade of hERG potassium channels. In the dog, foamy macrophages were observed in lymphoid tissue of various organs during repeat-dose toxicity studies. The finding was shown to be partially reversible; the clinical relevance of this finding is unknown. Repeat-dose toxicity studies in rabbits revealed an inhibitory effect of delamanid and/or its metabolites on vitamin K-dependent blood clotting. In rabbits reproductive studies, embryo-fetal toxicity was observed at maternally toxic dosages. Pharmacokinetic data in animals have shown excretion of delamanid/metabolites into breast milk. In lactating rats, the $C_{\text{max}}$ for delamanid in breast milk was 4-fold higher than that of the blood. In juvenile toxicity studies in rats, all delamanid treatment-related findings were consistent with those noted in adult animals.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

- Hypromellose phthalate
- Povidone (K-25)
- all-rac-α-Tocopherol
- Mannitol
- Crospovidone
- Sucralose
- Silica, colloidal hydrated
- Cherry micron OT-22685
- Calcium stearate
6.2 Incompatibilities

Not applicable.

6.3 Shelf life

5 years

6.4 Special precautions for storage

Store in the original package in order to protect from moisture and light.

6.5 Nature and contents of container

Aluminium/Aluminium blister:
48 tablets.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Otsuka Novel Products GmbH
Erika-Mann-Straße 21
80636 München
Germany

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/13/875/005

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORIZATION

Date of first authorisation: 28 April 2014
Date of latest renewal: 24 March 2023

10. DATE OF REVISION OF THE TEXT

<{MM/YYYY}>

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
ANNEX II

A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

E. SPECIFIC OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING AUTHORISATION
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturers responsible for batch release

Otsuka Novel Products GmbH
Erika-Mann-Straße 21
80636 München
Germany

R-Pharm Germany GmbH
Heinrich-Mack-Straße 35
89257 Illertissen
Germany

The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal products subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic safety update reports (PSURs)

The requirements for submission of PSURs for this medicinal product are set out in Article 9 of Regulation (EC) No 507/2006 and, accordingly, the marketing authorisation holder (MAH) shall submit PSURs every 6 months.

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk management plan (RMP)

The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

- Additional risk minimisation measures

The MAH should agree the educational material with the Member States, prior to launch.
In each Member State, the Marketing Authorisation Holder (MAH) shall agree the content and format of the educational material with the national competent authority and implement it prior to launch.

The MAH shall ensure that all healthcare professionals involved in the prescribing, dispensing, handling or administration of Deltyba are provided with educational material.

1. **The educational material for Healthcare Providers (HCPs)** shall address the following key elements:
   - SmPC
   - Drug-resistance
   - Risk of QT interval prolongation
   - Drug use during pregnancy
   - Drug use during breastfeeding.

2. **The educational material for Patients** to be provided via the HCPs to reinforce and supplement the information provided in the patient information leaflet. It shall address the following key elements:
   - Drug use during pregnancy
   - Drug use during breastfeeding.

**E. SPECIFIC OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING AUTHORISATION**

This being a conditional marketing authorisation and pursuant to Article 14-a of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following measures:

<table>
<thead>
<tr>
<th>Description</th>
<th>Due date</th>
</tr>
</thead>
<tbody>
<tr>
<td>In order to further investigate the use of delamanid in different combination treatment regimens as well as safety, the MAH should submit the results of the endTB (Evaluating Newly approved Drugs for multidrug-resistant TB) study, a randomized, controlled Phase III trial in adults and adolescents with multi-drug-resistant tuberculosis conducted by Médecins Sans Frontières, including an additional analysis of the data with a focus on the evaluation of delamanid based on an agreed statistical analysis plan.</td>
<td>Q3 2024</td>
</tr>
</tbody>
</table>
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
### PARTICULARS TO APPEAR ON THE OUTER PACKAGING

#### CARTONS FOR BLISTER PACKS

1. **NAME OF THE MEDICINAL PRODUCT**
   
   Deltyba 50 mg film-coated tablets
   delamanid

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**
   
   Each film-coated tablet contains 50 mg delamanid

3. **LIST OF EXCIPIENTS**
   
   Contains lactose. See leaflet for further information.

4. **PHARMACEUTICAL FORM AND CONTENTS**
   
   48 tablets

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**
   
   Read the package leaflet before use.
   Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**
   
   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**
   
   EXP

9. **SPECIAL STORAGE CONDITIONS**
   
   Store in the original package in order to protect from moisture.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**
<table>
<thead>
<tr>
<th>11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Otsuka Novel Products GmbH</td>
</tr>
<tr>
<td>Erika-Mann-Straße 21, 80636 München</td>
</tr>
<tr>
<td>Germany</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>12. MARKETING AUTHORISATION NUMBER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EU/1/13/875/004</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>13. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>14. GENERAL CLASSIFICATION FOR SUPPLY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>15. INSTRUCTIONS ON USE</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>16. INFORMATION IN BRAILLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deltyba 50 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>17. UNIQUE IDENTIFIER – 2D BARCODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2D barcode carrying the unique identifier included.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>18. UNIQUE IDENTIFIER - HUMAN READABLE DATA</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC</td>
</tr>
<tr>
<td>SN</td>
</tr>
<tr>
<td>NN</td>
</tr>
</tbody>
</table>
**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**Blisters (Alu/Alu)**

<table>
<thead>
<tr>
<th><strong>1. NAME OF THE MEDICINAL PRODUCT</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Deltyba 50 mg film-coated tablets</td>
</tr>
<tr>
<td>delamanid</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>2. NAME OF THE MARKETING AUTHORISATION HOLDER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>OTSUKA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>3. EXPIRY DATE</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>4. BATCH NUMBER</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>5. OTHER</strong></th>
</tr>
</thead>
</table>
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTONS FOR BLISTER PACKS

1. **NAME OF THE MEDICINAL PRODUCT**
   
   Deltyba 25 mg dispersible tablets
   delamanid

2. **STATEMENT OF ACTIVE SUBSTANCE(S)**
   
   Each dispersible tablet contains 25 mg delamanid

3. **LIST OF EXCIPIENTS**

4. **PHARMACEUTICAL FORM AND CONTENTS**
   
   48 dispersible tablets

5. **METHOD AND ROUTE(S) OF ADMINISTRATION**
   
   Read the package leaflet before use.
   Oral use

6. **SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**
   
   Keep out of the sight and reach of children.

7. **OTHER SPECIAL WARNING(S), IF NECESSARY**

8. **EXPIRY DATE**
   
   EXP

9. **SPECIAL STORAGE CONDITIONS**
   
   Store in the original package in order to protect from moisture and light.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**
| 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER | Otsuka Novel Products GmbH  
Erika-Mann-Straße 21, 80636 München  
Germany |
| 12. MARKETING AUTHORISATION NUMBER(S) | EU/1/13/875/005 |
| 13. BATCH NUMBER | Lot |
| 14. GENERAL CLASSIFICATION FOR SUPPLY | |
| 15. INSTRUCTIONS ON USE | |
| 16. INFORMATION IN BRAILLE | Deltyba 25 mg |
| 17. UNIQUE IDENTIFIER – 2D BARCODE | 2D barcode carrying the unique identifier included. |
| 18. UNIQUE IDENTIFIER - HUMAN READABLE DATA | PC  
SN  
NN |
**MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS**

**Blisters (Alu/Alu)**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deltyba 25 mg dispersible tablets</td>
</tr>
<tr>
<td>delamanid</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. NAME OF THE MARKETING AUTHORISATION HOLDER</th>
</tr>
</thead>
<tbody>
<tr>
<td>OTSUKA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4. BATCH NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lot</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. OTHER</th>
</tr>
</thead>
</table>
B. PACKAGE LEAFLET
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Deltyba is and what it is used for
2. What you need to know before you take Deltyba
3. How to take Deltyba
4. Possible side effects
5. How to store Deltyba
6. Contents of the pack and other information

1. What Deltyba is and what it is used for

Deltyba contains the active substance delamanid, an antibiotic for the treatment of tuberculosis in the lung caused by bacteria that are not killed by the most commonly used antibiotics to treat tuberculosis. It must always be taken together with other medicines for treating tuberculosis. Deltyba is used in adults, adolescents, children and infants who are weighing at least 10 kg.

2. What you need to know before you take Deltyba

Do not take Deltyba:
- if you are allergic to delamanid or any of the other ingredients of this medicine (listed in section 6).
- if you have very low levels of albumin, in the blood.
- if you are taking medicines that strongly increase the activity of a certain liver enzyme called ‘CYP450 3A4’ (e.g. carbamazepine [a medicine used to treat epilepsy and prevent seizures]).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before taking Deltyba. Before you start taking Deltyba, and during the treatment, your doctor may check your heart’s electrical activity using an ECG (electrocardiogram) machine (electrical recording of the heart). Your doctor may also perform a blood test to check the concentration of some minerals and proteins which are important for the function of your heart.

Tell your doctor if you have one of the following conditions:
- you have reduced levels of albumin, potassium, magnesium or calcium in the blood.
- you have been told that you have heart problems, for example a slow heart rhythm (bradycardia) or have a history of heart attack (myocardial infarction).
• if you have a condition called congenital long QT syndrome or have a serious heart disease or problems with heart rhythm.
• you have liver disease or severe kidney disease.

Children and adolescents
Deltysba is not suitable for children with a body weight of less than 10 kg because there are not enough data available in those patients to determine the correct doses.

Other medicines and Deltysba
Tell your doctor:
- if you are taking, have recently taken or might take any other medicines.
- if you are taking medicines to treat an abnormal heart rhythm (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol).
- if you are taking medicines to treat psychoses (e.g. phenothiazines, sertindole, sulthiapride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine) or depression.
- if you are taking certain antimicrobial medicines (e.g. erythromycin, clarithromycin, moxifloxacin, sparflaxacin, bedaquiline, or pentamidine).
- if you are taking triazole antifungal medicines (e.g. fluconazole, itraconazole, voriconazole).
- if you are taking certain medicines to treat allergic reactions (e.g. terfenadine, astemizole, mizolastine).
- if you are taking certain medicines to treat malaria (e.g. halofantrine, quinine, chloroquine, artesunate/amodiaquine, dihydroartesamine/verpamequine).
- if you are taking any of the following: cisapride (used to treat stomach disorders), droperidol (used against vomiting and migraine), domperidone (used against nausea and vomiting), diphenemil (used to treat stomach disorders or excessive sweating), probucol (lowers the level of cholesterol in the bloodstream), levomethadyl or methadone (used for the treatment of opiate addiction), vinca alkaloids (anti-cancer medicines), or arsenic trioxide (used to treat certain types of leukaemia).
- if you are taking HIV-medicines containing lopinavir/ritonavir, or saquinavir.

You may be more at risk for dangerous changes of the heart rhythm.

Pregnancy and breast-feeding
Deltysba may cause harm to an unborn baby. It is not usually recommended for use during pregnancy. It is important to tell your doctor if you are pregnant, think you may be pregnant, or are planning to get pregnant. Your doctor will weigh up the benefits to you against the risks to your baby of taking Deltysba whilst you are pregnant.

It is not known if delamanid passes into breast milk in humans. Breast-feeding is not recommended during treatment with Deltysba.

Driving and using machines
Deltysba is expected to have a moderate influence on your ability to drive and use machines. If you experience side effects that might affect your ability to concentrate and react, do not drive or use machines.

Deltysba 50 mg film-coated tablets contain lactose monohydrate.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.

3. How to take Deltysba
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose as advised by your doctor is:
Adults, adolescents and children with a body weight of 50 kg or more: two 50 mg film-coated tablets taken twice a day (morning and evening) for 24 weeks.
Children with a body weight of 30 kg or more and less than 50 kg: one 50 mg film-coated tablet taken twice daily for 24 weeks.

For children with a body weight of less than 30 kg please see the package leaflet for Deltyba 25 mg dispersible tablets.

The film-coated tablets must be taken during or just after a meal. Swallow the tablets with water.

**If you take more Deltyba than you should**
If you have taken more tablets than your prescribed dose, contact your doctor or your local hospital. Remember to take the pack with you so that it is clear what medicine you have taken.

**If you forget to take Deltyba**
If you forget a dose, take it as soon as you remember it. However, if it is nearly time for the next dose, just skip the missed dose.

Do not take a double dose to make up for a forgotten tablet.

**If you stop taking Deltyba**
DO NOT stop taking the tablets unless your doctor tells you to. Stopping too early could allow the bacteria to recover and to become resistant to delamanid.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Side effects very commonly (may affect more than 1 in 10 people) reported** in clinical studies with Deltyba were:

- Decreased appetite
- Disturbed sleep
- Feeling dizzy
- Feeling sick (nausea)
- Headache
- Stomach irritation (gastritis)
- Vomiting

**Side effects commonly (may affect up to 1 in 10 people) reported in** clinical studies with Deltyba were:

- Chest pain
- Decrease in the thyroid gland activity (hypothyroidism)
- Defect in cardiac rhythm that predisposes to fainting, dizziness and palpitations (electrocardiogram QT prolonged)
- Depression
- Feeling anxious (anxiety)
- Hallucination (seeing, hearing or feeling things that are not there)*
- Heart rhythm disturbance (atrioventricular block first degree)
- Indigestion (dyspepsia)
- Irregular heartbeats (ventricular extrasystoles)
- Muscular weakness
- Muscle spasms
- Numbness, decreased sensation in hands and/or feet (hypoesthesia)
- Pounding heartbeat (palpitations)
- Rise in the level of cortisol in your blood
• Shakiness (often in the hands) (tremor)
• Signs of psychosis: a loss of contact with reality, such as hearing voices or seeing things that are not there
• Throat irritation

*Cases were mostly reported in children.

**Side effects uncommonly (may affect up to 1 in 100 people) reported** in clinical studies with Deltyba were:
• Lack of energy (lethargy)

**Reporting of side effects**
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Deltyba**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton or blister after ‘EXP:’. The expiry date refers to the last day of that month.

Store in the original package in order to protect from moisture.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Deltyba 50 mg film-coated tablets contain**
- One film-coated tablet contains 50 mg of the active substance delamanid.
- The other ingredients are hypromellose phthalate, povidone, all-rac-α-tocopherol, microcrystalline cellulose, sodium starch glycolate, carmellose calcium, colloidal hydrated silica, magnesium stearate, lactose monohydrate, hypromellose, macrogol 8000, titanium dioxide, talc, iron oxide (E172).

**What Deltyba 50 mg film-coated tablets look like and contents of the pack**
Deltyba 50 mg film-coated tablets are round, and yellow.

Deltyba is supplied in packs of 48 film-coated tablets in aluminium/aluminium blisters.

**Marketing Authorisation Holder and Manufacturer**

**Marketing Authorisation Holder:**
Otsuka Novel Products GmbH
Erika-Mann-Straße 21
80636 München
Germany
**Tel:** +49 (0)89 206020 500

**Manufacturer:**
R-Pharm Germany GmbH
Heinrich-Mack-Straße 35
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

**BE**  
Otsuka Novel Products GmbH  
Tél/Tel: +49 (0)89 206020 500

**BG**  
Otsuka Novel Products GmbH  
Tel.: +49 (0)89 206020 500

**CZ**  
Otsuka Novel Products GmbH  
Tel: +49 (0)89 206020 500

**DK**  
Otsuka Novel Products GmbH  
Tlf: +49 (0)89 206020 500

**DE**  
Otsuka Novel Products GmbH  
Tel: +49 (0)89 206020 500

**EE**  
Otsuka Novel Products GmbH  
Tel: +49 (0)89 206020 500

**EL**  
Otsuka Novel Products GmbH  
Τηλ: +49 (0)89 206020 500

**ES**  
Otsuka Pharmaceutical S.A.  
Tel: +34 93 208 10 20

**FR**  
Otsuka Pharmaceutical France SAS  
Tél.: +33 (0)1 47 08 00 00

**HR**  
Otsuka Novel Products GmbH  
Tel: +49 (0)89 206020 500

**IE**  
Otsuka Novel Products GmbH  
Tel: +49 (0)89 206020 500

**IS**  
Otsuka Novel Products GmbH  
Sími: +49 (0)89 206020 500

**IT**  
Otsuka Pharmaceutical Italy S.r.l.  
Tel: +39 (0)2 00632710

**LT**  
Otsuka Novel Products GmbH  
Tel: +49 (0)89 206020 500

**LU**  
Otsuka Novel Products GmbH  
Tél/Tel: +49 (0)89 206020 500

**HU**  
Otsuka Novel Products GmbH  
Tel.: +49 (0)89 206020 500

**MT**  
Otsuka Novel Products GmbH  
Tel: +49 (0)89 206020 500

**NO**  
Otsuka Novel Products GmbH  
Tlf: +49 (0)89 206020 500

**AT**  
Otsuka Novel Products GmbH  
Tel: +49 (0)89 206020 500

**PL**  
Otsuka Novel Products GmbH  
Tel.: +49 (0)89 206020 500

**PT**  
Otsuka Novel Products GmbH  
Tel: +49 (0)89 206020 500

**RO**  
Ewopharma România SRL  
Tel.: +40 (0)21 260 13 44; +40 (0)21 260 14 07

**SI**  
Otsuka Novel Products GmbH  
Tel: +49 (0)89 206020 500

**SK**  
Otsuka Novel Products GmbH  
Tel: +49 (0)89 206020 500

**FI**  
Otsuka Novel Products GmbH  
Puh/Tel: +49 (0)89 206020 500
This leaflet was last revised in <\{MM/YYYY\}>

This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.
The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.
Package leaflet: Information for the patient

Deltyba 25 mg dispersible tablets
delamanid

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Deltyba is and what it is used for
2. What you need to know before you take Deltyba
3. How to take Deltyba
4. Possible side effects
5. How to store Deltyba
6. Contents of the pack and other information

1. What Deltyba is and what it is used for

Deltyba contains the active substance delamanid, an antibiotic for the treatment of tuberculosis in the lung caused by bacteria that are not killed by the most commonly used antibiotics to treat tuberculosis. It must always be taken together with other medicines for treating tuberculosis. Deltyba is used in adults, adolescents, children and infants who are weighing at least 10 kg.

2. What you need to know before you take Deltyba

Do not take Deltyba:
- if you are allergic to delamanid or any of the other ingredients of this medicine (listed in section 6).
- if you have very low levels of albumin, in the blood.
- if you are taking medicines that strongly increase the activity of a certain liver enzyme called ‘CYP450 3A4’ (e.g. carbamazepine [a medicine used to treat epilepsy and prevent seizures]).

Warnings and precautions

Talk to your doctor, pharmacist or nurse before taking Deltyba. Before you start taking Deltyba, and during the treatment, your doctor may check your heart’s electrical activity using an ECG (electrocardiogram) machine (electrical recording of the heart). Your doctor may also perform a blood test to check the concentration of some minerals and proteins which are important for the function of your heart.

Tell your doctor if you have one of the following conditions:
• you have reduced levels of albumin, potassium, magnesium or calcium in the blood.
• you have been told that you have heart problems, for example a slow heart rhythm (bradycardia) or have a history of heart attack (myocardial infarction).
if you have a condition called congenital long QT syndrome or have a serious heart disease or problems with heart rhythm.

you have liver disease or severe kidney disease.

Children and adolescents
Deltbya is not suitable for children with a body weight of less than 10 kg because there are not enough data available in those patients to determine the correct doses.

Other medicines and Deltbya
Tell your doctor:
- if you are taking, have recently taken or might take any other medicines.
- if you are taking medicines to treat an abnormal heart rhythm (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol).
- if you are taking medicines to treat psychoses (e.g. phenothiazines, sertindole, sulthiame, chlorpromazine, haloperidol, melperone, mesoridazine, pimozide, or thioridazine) or depression.
- if you are taking certain antimicrobial medicines (e.g. erythromycin, clarithromycin, moxifloxacin, sparfolacin, bedaquiline, or pentamidine).
- if you are taking triazole antifungal medicines (e.g. fluconazole, itraconazole, voriconazole).
- if you are taking certain medicines to treat allergic reactions (e.g. terfenadine, astemizole, mizolastine).
- if you are taking certain medicines to treat malaria (e.g. halofantrine, quinine, chloroquine, artesunate/amodiaquine, dihydroartemisinin/piperaquine).
- if you are taking any of the following: cisapride (used to treat stomach disorders), droperidol (used against vomiting and migraine), domperidone (used against nausea and vomiting), diphenamid (used to treat stomach disorders or excessive sweating), probucol (lowers the level of cholesterol in the bloodstream), levomethadyl or methadone (used for the treatment of opiate addiction), vinca alkaloids (anti-cancer medicines), or arsenic trioxide (used to treat certain types of leukaemia).
- if you are taking HIV-medicines containing lopinavir/ritonavir, or saquinavir.

You may be more at risk for dangerous changes of the heart rhythm.

Pregnancy and breast-feeding
Deltbya may cause harm to an unborn baby. It is not usually recommended for use during pregnancy. It is important to tell your doctor if you are pregnant, think you may be pregnant, or are planning to get pregnant. Your doctor will weigh up the benefits to you against the risks to your baby of taking Deltbya whilst you are pregnant.

It is not known if delamanid passes into breast milk in humans. Breast-feeding is not recommended during treatment with Deltbya.

Driving and using machines
Deltbya is expected to have a moderate influence on your ability to drive and use machines. If you experience side effects that might affect your ability to concentrate and react, do not drive or use machines.

3. How to take Deltbya

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose as advised by your doctor is:
Children with a body weight of 20 kg or more and less than 30 kg: two 25 mg dispersible tablets in the morning and one 25 mg dispersible tablet in the evening.
Children with a body weight of 10 kg or more and less than 20 kg: one 25 mg dispersible tablet in the morning and one 25 mg dispersible tablet in the evening.
For children with a body weight of 30 kg or more please see the package leaflet for Deltyba 50 mg film-coated tablets.

The dispersible tablets must be taken during or just after a meal.

Place the 25 mg dispersible tablet(s) in a glass or a cup. Pour 10 to 15 mL of water (approximately 1 tablespoon) per 25 mg dispersible tablet in the cup or the glass. Wait until the dispersible tablet(s) dissolve(s) completely (approximately 30 seconds) and gently swirl to make a uniform suspension. The resulting whitish suspension must be ingested immediately. Thereafter, a further 10 to 15 mL of water (approximately 1 tablespoon) per 25 mg dispersible tablet must be added to the glass or cup, swirl gently ensuring that potentially remaining suspension is dispersed and the resulting suspension must also be ingested immediately.

**If you take more Deltyba than you should**
If you have taken more tablets than your prescribed dose, contact your doctor or your local hospital. Remember to take the pack with you so that it is clear what medicine you have taken.

**If you forget to take Deltyba**
If you forget a dose, take it as soon as you remember it. However, if it is nearly time for the next dose, just skip the missed dose.

Do not take a double dose to make up for a forgotten tablet.

**If you stop taking Deltyba**
DO NOT stop taking the tablets unless your doctor tells you to. Stopping too early could allow the bacteria to recover and to become resistant to delamanid.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. **Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Side effects very commonly (may affect more than 1 in 10 people) reported** in clinical studies with Deltyba were:
- Decreased appetite
- Disturbed sleep
- Feeling dizzy
- Feeling sick (nausea)
- Headache
- Stomach irritation (gastritis)
- Vomiting

**Side effects commonly (may affect up to 1 in 10 people) reported** in clinical studies with Deltyba were:
- Chest pain
- Decrease in the thyroid gland activity (hypothyroidism)
- Defect in cardiac rhythm that predisposes to fainting, dizziness and palpitations (electrocardiogram QT prolonged)
- Depression
- Feeling anxious (anxiety)
- Hallucination (seeing, hearing or feeling things that are not there)*
- Heart rhythm disturbance (atrioventricular block first degree)
- Indigestion (dyspepsia)
- Irregular heartbeats (ventricular extrasystoles)
- Muscular weakness
- Muscle spasms
- Numbness, decreased sensation in hands and/or feet (hypoesthesia)
- Pounding heartbeat (palpitations)
- Rise in the level of cortisol in your blood
- Shakiness (often in the hands) (tremor)
- Signs of psychosis: a loss of contact with reality, such as hearing voices or seeing things that are not there
- Throat irritation

*Cases were mostly reported in children.

**Side effects uncommonly (may affect up to 1 in 100 people) reported** in clinical studies with Deltyba were:
- Lack of energy (lethargy)

### Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Deltyba**

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton or blister after ‘EXP:’. The expiry date refers to the last day of that month.

Store in the original package in order to protect from moisture and light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. **Contents of the pack and other information**

**What Deltyba 25 mg dispersible tablets contain**
- One dispersible tablet contains 25 mg of the active substance delamanid.
- The other ingredients are hypromellose phthalate, povidone (K-25), all-rac-α-tocopherol, mannitol, crospovidone, sucralose, colloidal hydrated silica, cherry micron OT-22685, calcium stearate.

**What Deltyba 25 mg dispersible tablets look like and contents of the pack**
Deltyba 25 mg dispersible tablets are round, and white to off-white.

Deltyba is supplied in packs of 48 dispersible tablets in aluminium/aluminium blisters.

**Marketing Authorisation Holder and Manufacturer**
Marketing Authorisation Holder:
Otsuka Novel Products GmbH
Erika-Mann-Straße 21
80636 München
Germany
Manufacturer:
R-Pharm Germany GmbH
Heinrich-Mack-Straße 35
89257 Illertissen
Germany

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

<table>
<thead>
<tr>
<th>Country</th>
<th>Contact Person</th>
<th>Telephone</th>
</tr>
</thead>
<tbody>
<tr>
<td>BE</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>BG</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>CZ</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>DK</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>DE</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>EE</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>EL</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>ES</td>
<td>Otsuka Pharmaceutical S.A.</td>
<td>+34 93 208 10 20</td>
</tr>
<tr>
<td>FR</td>
<td>Otsuka Pharmaceutical France SAS</td>
<td>+33 (0)1 47 08 00 00</td>
</tr>
<tr>
<td>HR</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>IE</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>LT</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>LU</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>HU</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>MT</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>NL</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>NO</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>AT</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>PL</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>PT</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
<tr>
<td>RO</td>
<td>Ewopharma România SRL</td>
<td>+40 (0)21 260 13 44; +40 (0)21 260 14 07</td>
</tr>
<tr>
<td>SI</td>
<td>Otsuka Novel Products GmbH</td>
<td>+49 (0)89 206020 500</td>
</tr>
</tbody>
</table>
This leaflet was last revised in <{MM/YYYY}>.

This medicine has been given ‘conditional approval’. This means that there is more evidence to come about this medicine.
The European Medicines Agency will review new information on this medicine at least every year and this leaflet will be updated as necessary.

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu. There are also links to other websites about rare diseases and treatments.